Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies

Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments

Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development

Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.